ARCUTIS BIOTHERAPEUTICS, INC. Revenue from Contract with Customer, Including Assessed Tax
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Revenue from Contract with Customer, Including Assessed Tax of $129.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $129.86M, a 59.33% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $105.40M, a 65.08% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $127.50M, a 83.83% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $99.22M, a 121.69% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2025 was $372.07M, a 123.41% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2024 was $166.54M, a 470.62% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2023 was $29.19M, a 691.81% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2022 was $3.69M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 12 month | Revenue from Contract with Customer, Including Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $129.86M 10-Q · filed 2026-08-05 | $235.26M 10-Q · filed 2026-08-05 | $362.76M derived: sum of 3 quarters · filed 2026-08-05 | $461.98M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $105.40M 10-Q · filed 2026-05-06 | $232.90M derived: sum of 2 quarters · filed 2026-05-06 | $332.12M derived: sum of 3 quarters · filed 2026-05-06 | $413.62M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $127.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $226.72M derived: sum of 2 quarters · filed 2026-02-25 | $308.23M derived: sum of 3 quarters · filed 2026-08-05 | $372.07M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $99.22M 10-Q · filed 2025-10-28 | $180.72M derived: sum of 2 quarters · filed 2026-08-05 | $244.57M 10-Q · filed 2025-10-28 | $313.93M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $81.50M 10-Q · filed 2026-08-05 | $145.35M 10-Q · filed 2026-08-05 | $214.71M derived: sum of 3 quarters · filed 2026-08-05 | $259.46M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $63.85M 10-Q · filed 2026-05-06 | $133.21M derived: sum of 2 quarters · filed 2026-05-06 | $177.96M derived: sum of 3 quarters · filed 2026-05-06 | $208.82M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $69.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $114.11M derived: sum of 2 quarters · filed 2026-02-25 | $144.97M derived: sum of 3 quarters · filed 2026-02-25 | $166.54M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $44.76M 10-Q · filed 2025-10-28 | $75.61M derived: sum of 2 quarters · filed 2025-10-28 | $97.18M 10-Q · filed 2025-10-28 | $110.71M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | $30.86M 10-Q · filed 2025-08-06 | $52.43M 10-Q · filed 2025-08-06 | $65.95M derived: sum of 3 quarters · filed 2026-02-25 | $74.06M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-03-31 | $21.57M 10-Q · filed 2025-05-06 | $35.09M derived: sum of 2 quarters · filed 2026-02-25 | $43.20M derived: sum of 3 quarters · filed 2026-02-25 | $47.97M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2023-12-31 | $13.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $21.64M derived: sum of 2 quarters · filed 2026-02-25 | $26.41M derived: sum of 3 quarters · filed 2026-02-25 | $29.19M 10-K · filed 2026-02-25 | $59.61M 10-K · filed 2024-02-27 | ||
| 2023-09-30 | $8.11M 10-Q · filed 2024-11-06 | $38.11M 10-Q · filed 2023-11-03 | $12.88M derived: sum of 2 quarters · filed 2024-11-06 | $15.66M 10-Q · filed 2024-11-06 | $46.08M 10-Q · filed 2023-11-03 | $18.62M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-06-30 | $4.77M 10-Q · filed 2024-08-14 | $7.55M 10-Q · filed 2024-08-14 | $10.51M derived: sum of 3 quarters · filed 2025-02-25 | $11.24M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-03-31 | $2.78M 10-Q · filed 2024-05-14 | $5.74M derived: sum of 2 quarters · filed 2025-02-25 | $6.47M derived: sum of 3 quarters · filed 2025-02-25 | $6.47M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2022-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $3.69M derived: sum of 2 quarters · filed 2025-02-25 | $3.69M derived: sum of 3 quarters · filed 2025-02-25 | $3.69M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $725.00K 10-Q · filed 2023-11-03 | $725.00K derived: sum of 2 quarters · filed 2023-11-03 | $725.00K 10-Q · filed 2023-11-03 | $725.00K derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-02-27 | $0.00 derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $0.00 derived: sum of 3 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $0.00 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |||||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |